Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on June 2, 2016, in Marseille, France. All...

Update on strategy and pipeline Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and...

Cash, cash equivalents and financial instruments of the Company amounted to €255.8 million ; Broad innovative pipeline including three clinical-stage programs; expect first clinical data in 2016; Two...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the second quarter of 2016: Gilbert Dupont...

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 2, 2016, at 10:00 am in its headquarters, 117 avenue de Luminy...

Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models. Innate Pharma and OREGA Biotech today presented preclinical data on IPH52, a new CD39 checkpoint inhibitor program, at the...

Preclinical data demonstrate enhanced anti-tumor efficacy by combining PD-1/PD-L1 pathway blockade and NKG2A checkpoint inhibitor; Resistance to PD-1 pathway blockers is associated with upregulation...

Novel antibodies identified that block the CD73 immune checkpoint for cancer immunotherapy; Strengthens Innate’s positioning in targeting the tumor microenvironment. Innate Pharma SA (the “Company” -...

First-in-class anti-MICA/B therapeutic antibody; New data demonstrate dual mechanism of action of IPH4301, including tumor antigen targeting and immunomodulation; IND-enabling studies starting in 2016...

Five posters presented by Innate Pharma and collaborators; New data further supporting the rationale of four of Innate’s clinical and preclinical programs; New checkpoint inhibitor program targeting...